Want to join the conversation?
$BCR's 3Q15 sales from surgical graft were up 4% in 3Q15. The Endovascular business sales grew 18%, excluding the royalty payment from Gore. Within the Endovascular business, biopsy products climbed 14%, driven by healthy growth across the U.S. and even better performance internationally.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.